Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive
acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients
may or may not be receiving anticholinesterase agents. A common treatment for patients with
this disease includes the administration of intravenous immunoglobulin (IVIG), which is a
plasma protein that is given to help maintain adequate antibody levels to prevent infections
and decrease the symptoms of the disease of Myasthenia Gravis. This study is being done to
test if giving this medication in a subcutaneous form (into the fat of the abdomen, legs and
thighs) will be better tolerated for patients with Myasthenia Gravis.